Sunmax Biotechnology Co Ltd Asset Resilience Ratio
Sunmax Biotechnology Co Ltd asset resilience ratio. Sunmax Biotechnology Co Ltd (4728) has an Asset Resilience Ratio of 10.53% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 4728 cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Sunmax Biotechnology Co Ltd (2016–2024)
Asset resilience ratio of Sunmax Biotechnology Co Ltd from 2016 to 2024. This chart shows how Sunmax Biotechnology Co Ltd's Asset Resilience Ratio has changed over time. Read 4728 total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Sunmax Biotechnology Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Sunmax Biotechnology Co Ltd (4728) total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$200.00 Million | 10.53% |
| Total Liquid Assets | NT$200.00 Million | 10.53% |
Asset Resilience Insights
- Moderate Liquidity: Sunmax Biotechnology Co Ltd has 10.53% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Sunmax Biotechnology Co Ltd Industry Peers by Asset Resilience Ratio
Compare Sunmax Biotechnology Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Sk Biopharmaceuticals Co Ltd
KO:326030 |
Biotechnology | 0.14% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Ideaya Biosciences Inc
NASDAQ:IDYA |
Biotechnology | 47.46% |
|
Inner Mongolia Furui Med Sci
SHE:300049 |
Biotechnology | 3.03% |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229 |
Biotechnology | 0.12% |
|
Hyundai Bioscience Co. Ltd
KQ:048410 |
Biotechnology | 18.85% |
|
DNA Link Inc
KQ:127120 |
Biotechnology | 0.00% |
Sunmax Biotechnology Co Ltd Asset Resilience Ratio by Year (2016–2024)
Sunmax Biotechnology Co Ltd asset resilience ratio by year from 2016 to 2024. The table below shows the annual Asset Resilience Ratio data for Sunmax Biotechnology Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 4.86% | NT$90.00 Million ≈ $2.84 Million |
NT$1.85 Billion ≈ $58.31 Million |
-0.10pp |
| 2023-12-31 | 4.96% | NT$107.10 Million ≈ $3.37 Million |
NT$2.16 Billion ≈ $68.02 Million |
-7.72pp |
| 2022-12-31 | 12.68% | NT$227.37 Million ≈ $7.16 Million |
NT$1.79 Billion ≈ $56.50 Million |
+7.50pp |
| 2021-12-31 | 5.17% | NT$76.79 Million ≈ $2.42 Million |
NT$1.48 Billion ≈ $46.75 Million |
-4.43pp |
| 2020-12-31 | 9.60% | NT$131.01 Million ≈ $4.13 Million |
NT$1.36 Billion ≈ $42.98 Million |
-3.38pp |
| 2019-12-31 | 12.98% | NT$144.42 Million ≈ $4.55 Million |
NT$1.11 Billion ≈ $35.05 Million |
-14.99pp |
| 2018-12-31 | 27.97% | NT$211.95 Million ≈ $6.68 Million |
NT$757.89 Million ≈ $23.88 Million |
+8.08pp |
| 2017-12-31 | 19.88% | NT$131.40 Million ≈ $4.14 Million |
NT$660.92 Million ≈ $20.82 Million |
+17.70pp |
| 2016-12-31 | 2.19% | NT$13.06 Million ≈ $411.43K |
NT$597.49 Million ≈ $18.82 Million |
-- |
About Sunmax Biotechnology Co Ltd
Sunmax Biotechnology Co., Ltd., a biomedical company, develops, manufactures, and markets biomedical grade collagen and skin care product in Taiwan and Mainland China. The company offers dermal fillers, including Sunmax Deusaderm VITAL and Sunmax Deusaderm LIDO Injectable Collagen Gel with Lidocaine. The company was founded in 2001 and is headquartered in Tainan City, Taiwan.